Psilocybin (COMP360) vs VLS-01

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline

Psilocybin (COMP360)

Developed by COMPASS Pathways

Phase 3 in Major Depressive Disordersmall molecule
Reliable signal

NCT05711940 · Phase 3 · active, not recruiting

This was a randomized, quadruple-blinded, active-comparator-controlled trial with a large sample size (572 participants) and a primary endpoint (MADRS depression score change) that is a validated, hard clinical measure of disease severity, not a lab biomarker. The primary comparison between the high dose and low-dose control arm reached statistical significance in the favorable direction (p<0.001), meeting the design's own pre-specified success criteria.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2029 · NCT06132178 (registry estimate)

Reported efficacy

COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. (Week 6): COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. (met)

Result source: NCT05711940

VLS-01

Developed by AtaiBeckley Inc. and partners

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPsilocybin (COMP360)VLS-01
MADRS, change (acute)-12 vs -6.8−5.2 vs placebo25 mg · wk 3 · n 79NCT03775200—Not reported
CGI-S, change (acute)—Not posted · NCT05624268—Not reported
MADRS response—Not posted · NCT05624268—Not reported
MADRS remission—Not posted · NCT05624268—Not reported
Relapse (% of patients)—Not posted · NCT05624268—Not reported

MADRS, change (acute)

Psilocybin (COMP360)
-12 vs -6.8−5.2 vs placebo25 mg · wk 3 · n 79NCT03775200
VLS-01
—Not reported

CGI-S, change (acute)

Psilocybin (COMP360)
—Not posted · NCT05624268
VLS-01
—Not reported

MADRS response

Psilocybin (COMP360)
—Not posted · NCT05624268
VLS-01
—Not reported

MADRS remission

Psilocybin (COMP360)
—Not posted · NCT05624268
VLS-01
—Not reported

Relapse (% of patients)

Psilocybin (COMP360)
—Not posted · NCT05624268
VLS-01
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VLS-01: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Psilocybin (COMP360): 3 of 4 rows · VLS-01: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPsilocybin (COMP360)
Dropout rate
0%25 mga
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
6.3%25 mg
NCT03775200 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—25 mga
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
—25 mg
NCT03775200 · Phase 2 · registry result, not featured evidence
Serious AEs
0%25 mga
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
6.3%25 mg
NCT03775200 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
25 mga
headache 31.6%
blood pressure increased 15.8%
depression 5.3%
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
25 mg
headache 34.2% (placebo 25.3%)
nausea 22.8% (placebo 5.1%)
fatigue 15.2% (placebo 8.9%)
NCT03775200 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Psilocybin (COMP360)

MADRS -14.9 score @ 3wk25 mg
absolute change · score
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence
show 1 more result
-3.6 score @ 6wkCOMP360 25 mg
NCT05624268 · Phase 3 · sponsor-reported, not registry data
MADRS 42.1% (n=19) @ 3wk25 mg
responder rate · % of participants
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
MADRS Remission 42.1% (n=19) @ 3wk25 mg
responder rate · % of participants
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
CGI-S -1.3 score @ 3wk25 mg
absolute change · score
No placebo or comparator arm
NCT04739865 · Phase 2 · registry result, not featured evidence
MADRS -12 vs -6.8 placebo score @ 3wk25 mg
absolute change · score
NCT03775200 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Psilocybin (COMP360)'s landscape · VLS-01's landscape